BeOne Medicines (BEIGF) Operating Leases (2019 - 2026)

BeOne Medicines (BEIGF) has 8 years of Operating Leases data on file, last reported at $49.7 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $49.7 million, down 9.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.7 million (down 9.52% YoY), and the FY2025 annual result was $52.9 million, down 14.41% from the prior year.
• Operating Leases declined to $49.7 million in Q1 2026 per BEIGF's latest filing, from $52.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $61.9 million in Q4 2024 and troughed at $17.7 million in Q1 2024.
• A 5-year average of $42.1 million and a median of $41.9 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases slumped 45.54% in 2024, then jumped 209.76% in 2025.
• A 5-year view of Operating Leases shows it stood at $58.6 million in 2022, then retreated by 24.52% to $44.2 million in 2023, then soared by 39.94% to $61.9 million in 2024, then decreased by 14.41% to $52.9 million in 2025, then declined by 6.18% to $49.7 million in 2026.
• Business Quant data shows BEIGF's Operating Leases at $49.7 million in Q1 2026, $52.9 million in Q4 2025, and $51.4 million in Q3 2025.